Sign in
TerminatedPhase 1

A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies

Key facts

Who runs it
IGM Biosciences, Inc.
Where
Palo Alto, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 1
People taking part
2 people enrolled
Started
29 May 2024
Ended
21 Jan 2025
Type of study
Interventional
Treatments tested
  • Imvotamab
Record updated
11 February 2025
Why it stopped
Program Discontinuation

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Age ≥ 18 years at the time of signing ICF
  • Diagnosis of probable or definite IIM according to the 2017 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for IIM with subgroup classification of either DM, polymyositis (PM), anti-synthetase syndrome, or immune-mediated necrotizing myositis (IMNM)
  • Active IIM despite treatment with corticosteroids and at least 1 immunosuppressive or immunomodulatory standard-of-care agent determined at the discretion of the investigator after at least 3 months of treatment
  • If using oral corticosteroids (OCS), must be on a stable dose equivalent to ≤ 30 mg/day of prednisone for at least 4 weeks prior to first study treatment

Who cannot take part

  • Receipt of an investigational therapy less than 12 weeks or 5 drug-elimination half-lives (whichever is longer) prior to first administration of study treatment and during the study
  • Has inclusion body myositis or myositis-associated with other connective tissue disease
  • Pregnant or breastfeeding or intending to become pregnant during the study or within 3 months after the final dose of imvotamab

Where in United States

  • Standford UniversityPalo Alto, United States

About the trial

What the trial wants to find out

The purpose of this study is to determine the safety and tolerability of imvotamab in patients with Moderate-Severe Idiopathic Inflammatory Myopathies who have failed prior therapies.

Read full original descriptionShow less

Participants will be given imvotamab through a vein (i.e., intravenously).

The group in the trial

  • Imvotamab (Dose Escalation)Treatment being tested

    Imvotamab administered intravenously

    Treatment: Imvotamab

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Imvotamab in Adult Participants With Active, Refractory Moderate-Severe Idiopathic Inflammatory Myopathies
Record updated
11 February 2025